Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas
March 2018
in “
Frontiers in Immunology
”
TLDR The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.
The document from 2018 discusses the complexities of defining and understanding Systemic Lupus Erythematosus (SLE), particularly the challenges in using anti-double-stranded DNA (anti-dsDNA) antibodies as biomarkers due to their presence in various diseases and conditions beyond SLE. It highlights the lack of consensus on the criteria for classifying SLE, the diversity of clinical phenotypes, and the need for a more integrated approach to better define and treat the syndrome. The document also questions the current definition of SLE as a syndrome and the diagnostic value of anti-dsDNA antibodies, suggesting that more research is needed to understand the biological linkages between SLE manifestations and to develop precise classification criteria and treatment approaches. It concludes that anti-dsDNA antibodies are not exclusive to SLE and their role as biomarkers is questionable, emphasizing the need for a deeper understanding of the mechanisms behind their production.
